Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2015, Article ID 627631, 9 pages
Research Article

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

1Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
2Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
3Optum, 950 Winter Street, Suite 2800, Waltham, MA 02451, USA
4Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

Received 3 September 2015; Accepted 3 November 2015

Academic Editor: Salvatore Minisola

Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [7 citations]

The following is the list of published articles that have cited the current article.

  • T. Imai, S. Tanaka, K. Kawakami, T. Miyazaki, H. Hagino, and M. Shiraki, “Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial,” Osteoporosis International, 2017. View at Publisher · View at Google Scholar
  • Yuankun Zhai, Qingfeng Wang, Yingying Li, Jiawei Cui, Kun Feng, Xijian Kong, and Cory J. Xian, “The higher osteoprotective activity of psoralidin in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis,” Biomedicine & Pharmacotherapy, vol. 102, pp. 1015–1024, 2018. View at Publisher · View at Google Scholar
  • Yoshiya Tanaka, and Takeshi Ohira, “Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system,” Current Opinion in Pharmacology, vol. 40, pp. 110–119, 2018. View at Publisher · View at Google Scholar
  • Paige Morizio, Jena I. Burkhart, and Sachiko Ozawa, “Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients,” Annals of Pharmacotherapy, pp. 106002801876880, 2018. View at Publisher · View at Google Scholar
  • Saeko Fujiwara, Xiahong Zhao, Cheryl Teoh, Dena H. Jaffe, and Yurie Taguchi, “Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs,” Journal of Bone and Mineral Metabolism, 2018. View at Publisher · View at Google Scholar
  • Pilar Sáez-López, Iñigo Etxebarria-Foronda, Maria Pilar Mesa Lampre, Noelia Alonso García, and Natalia Sánchez Hernández, “Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly,” Revista Española de Geriatría y Gerontología, 2018. View at Publisher · View at Google Scholar
  • M. Hiligsmann, J.-Y. Reginster, A.N.A. Tosteson, S.V. Bukata, K.G. Saag, D.T. Gold, P. Halbout, F. Jiwa, E.M. Lewiecki, D. Pinto, J.D. Adachi, N. Al-Daghri, O. Bruyère, M. Chandran, C. Cooper, N.C. Harvey, T.A. Einhorn, J.A. Kanis, D.L. Kendler, O.D. Messina, R. Rizzoli, L. Si, and S. Silverman, “Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation,” Osteoporosis International, 2018. View at Publisher · View at Google Scholar